E-ISSN 1309-4866
Research Article
A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial
1 Department of Neurology, İstanbul Bilim University School of Medicine, İstanbul, Turkey  
2 Department of Neurology, Haydarpaşa Numune Training Research Hospital, İstanbul, Turkey  
3 İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, Nöroloji Ana Bilim Dalı, İstanbul, Türkiye  
4 Department of Neurology, Ege University School of Medicine, İzmir, Turkey  
5 Department of Neurology, Kocaeli University School of Medicine, Kocaeli, Turkey  
6 Department of Neurology, Uludağ University School of Medicine, Bursa, Turkey  
7 Department of Neurology, Marmara University School of Medicine İstanbul, Turkey  
8 Department of Neurology, Ondokuz Mayıs University School of Medicine, Samsun, Turkey  
9 Department of Neurology, Karadeniz Teknik University School of Medicine, Trabzon, Turkey  
10 Department of Neurology, Hacettepe University School of Medicine, Ankara, Turkey  
11 Department of Neurology, Gazi University School of Medicine, Ankara, Turkey  
12 Department of Medical, Novartis Pharmaceuticals Turkey, İstanbul, Turkey  
13 FINE Study Group  
Arch Neuropsychiatry ; : -
DOI: 10.5152/npa.2017.20515
This article was viewed 163 times, downloaded 0 times

Key Words: Multiple sclerosis, fingolimod, patient satisfaction, quality of life

Introduction: To assess satisfaction and quality of life in patients with relapsing–remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.


Methods: Patients aged 18–65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life.


Results: Forty-two patients (62% male; mean age: 35.7±9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related.


Conclusion: Large-scale comparative studies performed with disease-specific quality of life instruments will allow more information on this issue.

Key Words
Author's Corner
Latest Update: 29.12.2017